Larimar Therapeutics, Inc.
LRMR
$3.58
-$0.31-7.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -62.50M | -47.71M | -26.18M | -29.28M | -28.82M |
| Total Depreciation and Amortization | 87.00K | 88.00K | 87.00K | 88.00K | 77.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.32M | 1.39M | 1.29M | 1.02M | 1.17M |
| Change in Net Operating Assets | 22.56M | 17.48M | 5.42M | 1.63M | 5.76M |
| Cash from Operations | -38.53M | -28.75M | -19.38M | -26.54M | -21.82M |
| Capital Expenditure | 0.00 | -23.00K | -19.00K | -49.00K | -179.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 34.00M | 33.04M | 18.86M | 14.50M | 19.38M |
| Cash from Investing | 34.00M | 33.02M | 18.84M | 14.45M | 19.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 65.29M | -- | -- | 36.00K |
| Repurchase of Common Stock | -201.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -201.00K | 65.29M | -- | -- | 36.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.73M | 69.55M | -539.00K | -12.09M | -2.58M |